Grab an umbrella, it’s raining ⁠IPOs⁠!

This week, Lori, Greg and Tyler discuss the first ⁠surge of IPO activity⁠ this year plus gene therapy pricing,

The first ⁠surge of IPO activity⁠ this year sees Alto Neuroscience, ⁠ArriVent Biopharma⁠, ⁠CG Oncology⁠, Kyverna Therapeutics and Metagenomi making announcements.

Lori, Greg and Tyler also discuss ⁠gene therapy pricing⁠ including Vertex/CRISPR’s ⁠Casgevy⁠.

Lori Ellis is the head of insights at BioSpace, providing industry analysis as well as paid custom content for BioSpace clients. Her current focus is on the ever-evolving impact of technology on the pharmaceutical industry. You can reach her at lori.ellis@biospace.com. Follow her on LinkedIn.

Greg Slabodkin is the News Editor at BioSpace. You can reach him at greg.slabodkin@biospace.com. Follow him on LinkedIn.    

Tyler Patchen is a staff writer at BioSpace. You can reach him at tyler.patchen@biospace.com. Follow him on LinkedIn.


> Listen on Spotify

> Listen on Apple podcasts

> Listen on Amazon Music

> Listen on iheart


Lori Ellis is the Head of Insights at BioSpace. She analyzes and comments on industry trends for BioSpace and clients. Her current focus is on the ever-evolving impact of technology on the pharmaceutical industry. You can reach her at lori.ellis@biospace.com. Follow her on LinkedIn.
Greg is a seasoned editor/writer who has covered the healthcare, life sciences and medical device industries for several tech trade publications. Follow him on LinkedIn.
Tyler Patchen is a freelance writer based in Alabama. He was formerly staff writer at BioSpace. You can reach him at tpatchen94@gmail.com.
MORE ON THIS TOPIC